Form 4: TG Therapeutics Director Sagar Lonial Granted Over 14,000 Restricted Shares

TG Therapeutics, Inc. director Sagar Lonial was granted 14,718 restricted shares of common stock, vesting in June 2026, as disclosed in a recent SEC Form 4 filing.

Summary

• Sagar Lonial, a Director of TG Therapeutics, Inc. (TGTX), acquired 14,718 shares of common stock.
• The transaction occurred on June 12, 2025, and the shares were acquired at a price of $0, indicating a grant rather than a purchase.
• These 14,718 shares are restricted and are scheduled to vest on June 12, 2026.
• Following this transaction, Sagar Lonial beneficially owns a total of 114,913 shares of common stock in TG Therapeutics, Inc.
• The filing indicates that the transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of restricted shares to a director is a standard practice that aligns the director's interests with shareholders, indicating continued commitment and incentivization. While there's minor dilution, it's a common and expected part of compensation.

Positives

• The grant of restricted shares aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for retaining and incentivizing key personnel, including directors.

Negatives

• The issuance of new shares, even restricted ones, can lead to minor dilution for existing shareholders, although this is a common aspect of equity compensation plans.

Industry Context

This transaction represents a routine equity compensation event for a director, common across publicly traded companies in the biotechnology and pharmaceutical sectors. Such grants are part of standard corporate governance practices aimed at aligning management and director incentives with long-term shareholder value.

Related Party Transactions

• The grant of 14,718 restricted shares to Sagar Lonial, a director of TG Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: Experience minor dilution due to the issuance of new shares, but benefit from increased alignment of the director's interests with the company's long-term performance.
• Director (Sagar Lonial): Receives equity compensation, increasing their stake and financial incentive in the company's success.

Next Steps

• The 14,718 restricted shares granted to Sagar Lonial are scheduled to vest on June 12, 2026.

Key Dates

Keywords

TG Therapeutics, TGTX, Sagar Lonial, Restricted Stock Grant, SEC Form 4, Insider Transaction, Equity Compensation, Director Compensation, Stock Vesting